

NBCG PROGRAM

Møterom: TBA

Møteleder: Bjørn Naume og Ellen Schlichting, Oslo Universitetssykehus

- | | |
|---------------|--|
| 13:30 - 13:50 | Hormonbehandling og brystkreftisiko – metaanalyse av >100.000 individuelle pasienter gir svar Merethe Kumle, Universitetet i Tromsø |
| 13:50 - 14:15 | Mammadiologi inkludert MR diagnostikk – hva er nødvendig nå og hva trenger vi i morgen? Linda Romundstad, Drammen sykehus |
| 14:15 - 14:35 | Optimal kirurgisk behandling av brystkreft – nye teknikker for merking av mammapreparat Vegard Brun, Universitetssykehuset i Nord-Norge |
| 14:35 - 15:00 | Neoadjuvant behandling i PETREMAC studien – har vi lært noe om hvordan CDK4/6 hemmere eller PARP hemmere kan benyttes? Hans Petter Eikesdal, Haukeland Universitetssykehus |
| 15:00 - 15:20 | Ferdigbehandlet, men... Flen Harris Utne, brystkreftoverlever og leder av Brystkreftforeningen |
| 15:20 - 15:45 | Pause |
| 15:45 - 16:45 | Oversikt over kliniske intervensjonsstudier med pågående inklusjon i Norge (4 min. presentasjoner) <ol style="list-style-type: none">1. POSITIVE (NBCG16) - Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer. Anna Sætersdal, Oslo Universitetssykehus2. ALICE (NBCG 17) - Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer. Jon Amund Kyte/Andreas Røssevold, Oslo Universitetssykehus3. ICON (NBCG18) - A randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with luminal B breast cancer. Jon Amund Kyte/Nikolai K Andresen, Oslo Universitetssykehus4. EMIT1 (NBCG19) - Establishment of Molecular profiling for Individual clinical routine Treatment decision in Early Breast Cancer. Hege O Ohnstad/Bjørn Naume, Oslo Universitetssykehus5. OPTIMA (NBCG20) - Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis. Hege O Ohnstad/Bjørn Naume, Oslo Universitetssykehus6. NATURAL (NBCG21) - Partial Breast Versus no Irradiation for Women >=60 Years Operated With Breast Conservation for Early Breast Cancer: a Clinically Controlled Randomized Phase III Trial. Ingvil Mjaaland, Stavanger Universitetssykehus7. Skagen Trial I - Hypofractionated Loco-regional Adjuvant Radiation Therapy of Breast Cancer Combined With a Simultaneous Integrated Boost. Ingvil Mjaaland, Stavanger Universitetssykehus8. I-BCT - Improved Breast Cancer Therapy (I-BCT-1) in the Neoadjuvant and Metastatic Setting. Olav Engebråten, Oslo Universitetssykehus9. Neo-BCT2 - Breast conserving surgery (BCT) after neoadjuvant therapy for large primary breast cancer (T2-T3) with infavourable tumor-to-breast size ratio. Helle Skjerven, Drammen Sykehus10. NEOLETEXE - Presurgical treatment with letrozole and exemestane in postmenopausal patients with ER-positive, locally advanced breast cancer: an intra-patient, cross-over trial. Jürgen Geisler, Akershus Universitetssykehus11. P53 bryststudien - Treatment of patients with advanced breast cancer harboring TP53 mutations with dose-dense cyclophosphamide. Hans Petter Eikesdal, Haukeland Universitetssykehus12. Intraoperativ strålebehandling av brystkreftpasienter. Steinar Lundgren, St. Olavs Hospital |
| 16:45 - 17:00 | Resultater fra Norsk Brystkreftregister Ellen Schlichting, Oslo Universitetssykehus |
| 17:00 - 17:30 | Nytt fra NBCG Egil Støre Blix, Universitetssykehuset i Nord-Norge |